Cancel
bluebird bio
bluebird bio Employees
10 people indexed:
-
4664k7h@hjh9pk876zs.0ph Sign up to see email
-
gv3j0v92f4@wxgp0g76tyz.fqz Sign up to see email
-
ff694zy1p42@1fj1pj4pp64.g86 Sign up to see email
-
a4s46z5803@xz018xppw21.nf1 Sign up to see email
-
Kasra Kasraian
Senior Vice President, Technical Development and Operations
yp5qp2vz3@h5253x767z8.gj1 Sign up to see emailq7f43x09g@zjjjfhyyzv9.yhg Sign up to see email -
Leslie Wilder
Vice President, Head of Regulatory Science
qx8g859@t4fnzfagys0.174 Sign up to see emailzvk3vn2@ngjkt6225vn.ksj Sign up to see email -
jk35848@t2gpq26t77q.4qx Sign up to see email
-
v41g70xf@2vqtyk56x0n.1j9 Sign up to see email
-
5gtz053n70@7t6z5119pxw.wgz Sign up to see email
-
y5s34g@hz57q9swf9h.wq5 Sign up to see email
bluebird bio Company Information
Bluebird bio is a biotechnology company focused on developing gene therapies for severe genetic diseases, including beta-thalassemia, cerebral adrenoleukodystrophy, and sickle cell disease. The company employs a proprietary lentiviral vector gene therapy platform to create treatments that aim to offer long-term solutions with a one-time therapy. Bluebird bio boasts the largest and deepest ex-vivo gene therapy data set globally. It has an FDA-approved gene therapy available for sickle cell disease and continues to conduct clinical trials to evaluate the safety and efficacy of its gene therapies. Additionally, the company supports the medical community and patients through sponsorships and advocacy grants, and engages in collaborations and licensing to expand the therapeutic potential of its technologies. Bluebird bio is also committed to ethical business practices, maintaining a comprehensive compliance and ethics program.
Report inaccurate information
Report inaccurate information
